Journal: International Journal of Pharmaceutics: X

Article Title: 3D printed matrix solid forms: Can the drug solubility and dose customisation affect their controlled release behaviour?

doi: 10.1016/j.ijpx.2022.100153

Figure Lengend Snippet: Chemical structure of different dexamethasone forms: (A) dexamethasone free acid (DEX); (B) dexamethasone acetate (DEX-A); and (C) dexamethasone phosphate (DEX-P).

Article Snippet: All printed solid forms and the PCL, DEX, DEX-A and DEX-P raw materials had their X-ray powder diffraction (XRPD) behaviour analysed by a Rigaku diffractometer (Tokyo Japan), using Cu Kα (λ = 0.154056 nm) as the radiation source, 40 kV voltage, 17 mA current, and a step of 0.05 in the range of 3–60 (2θ).

Techniques:

Journal: International Journal of Pharmaceutics: X

Article Title: 3D printed matrix solid forms: Can the drug solubility and dose customisation affect their controlled release behaviour?

doi: 10.1016/j.ijpx.2022.100153

Figure Lengend Snippet: Printlets (PRT) and mini-printlets (MPRT) prepared with 5% of different dexamethasone forms: dexamethasone free acid (DEX), dexamethasone acetate (DEX-A) and dexamethasone sodium phosphate (DEX-P).

Article Snippet: All printed solid forms and the PCL, DEX, DEX-A and DEX-P raw materials had their X-ray powder diffraction (XRPD) behaviour analysed by a Rigaku diffractometer (Tokyo Japan), using Cu Kα (λ = 0.154056 nm) as the radiation source, 40 kV voltage, 17 mA current, and a step of 0.05 in the range of 3–60 (2θ).

Techniques:

Journal: International Journal of Pharmaceutics: X

Article Title: 3D printed matrix solid forms: Can the drug solubility and dose customisation affect their controlled release behaviour?

doi: 10.1016/j.ijpx.2022.100153

Figure Lengend Snippet: Mechanical properties ( n = 6) of extruded filaments containing different DEX forms: dexamethasone free acid (DEX), dexamethasone acetate (DEX-A) and dexamethasone sodium phosphate (DEX-P). Results are expressed as mean ± SD.

Article Snippet: All printed solid forms and the PCL, DEX, DEX-A and DEX-P raw materials had their X-ray powder diffraction (XRPD) behaviour analysed by a Rigaku diffractometer (Tokyo Japan), using Cu Kα (λ = 0.154056 nm) as the radiation source, 40 kV voltage, 17 mA current, and a step of 0.05 in the range of 3–60 (2θ).

Techniques:

Journal: International Journal of Pharmaceutics: X

Article Title: 3D printed matrix solid forms: Can the drug solubility and dose customisation affect their controlled release behaviour?

doi: 10.1016/j.ijpx.2022.100153

Figure Lengend Snippet: Physicochemical characteristics of the printlets (PRT) and mini-printlets (MPRT) prepared with different DEX forms: dexamethasone free acid (DEX), dexamethasone acetate (DEX-A) and dexamethasone sodium phosphate (DEX-P). Results are expressed as mean ± SD.

Article Snippet: All printed solid forms and the PCL, DEX, DEX-A and DEX-P raw materials had their X-ray powder diffraction (XRPD) behaviour analysed by a Rigaku diffractometer (Tokyo Japan), using Cu Kα (λ = 0.154056 nm) as the radiation source, 40 kV voltage, 17 mA current, and a step of 0.05 in the range of 3–60 (2θ).

Techniques:

Journal: International Journal of Pharmaceutics: X

Article Title: 3D printed matrix solid forms: Can the drug solubility and dose customisation affect their controlled release behaviour?

doi: 10.1016/j.ijpx.2022.100153

Figure Lengend Snippet: Thermal and X-ray powder diffraction (XRPD) analyses of the 3D printed forms and the PCL, DEX, DEX-A and DEX-P raw materials: thermogravimetric analysis (TGA) thermograms (A, D and G); differential scanning calorimetry (DSC) thermograms (B, E and H); and XRPD) patterns (C, F and I).

Article Snippet: All printed solid forms and the PCL, DEX, DEX-A and DEX-P raw materials had their X-ray powder diffraction (XRPD) behaviour analysed by a Rigaku diffractometer (Tokyo Japan), using Cu Kα (λ = 0.154056 nm) as the radiation source, 40 kV voltage, 17 mA current, and a step of 0.05 in the range of 3–60 (2θ).

Techniques: Differential Scanning Calorimetry

Journal: International Journal of Pharmaceutics: X

Article Title: 3D printed matrix solid forms: Can the drug solubility and dose customisation affect their controlled release behaviour?

doi: 10.1016/j.ijpx.2022.100153

Figure Lengend Snippet: Raman spectra mapping of DEX forms (DEX, DEX-A and DEX-P) and mannitol on the surface of the printlets (PRT).

Article Snippet: All printed solid forms and the PCL, DEX, DEX-A and DEX-P raw materials had their X-ray powder diffraction (XRPD) behaviour analysed by a Rigaku diffractometer (Tokyo Japan), using Cu Kα (λ = 0.154056 nm) as the radiation source, 40 kV voltage, 17 mA current, and a step of 0.05 in the range of 3–60 (2θ).

Techniques:

Journal: International Journal of Pharmaceutics: X

Article Title: 3D printed matrix solid forms: Can the drug solubility and dose customisation affect their controlled release behaviour?

doi: 10.1016/j.ijpx.2022.100153

Figure Lengend Snippet: In vitro drug release profiles from formulations prepared with different sizes (printlets – PRT and mini-printlets – MPRT) and DEX form (dexamethasone free acid – DEX; dexamethasone acetate – DEX-A; and dexamethasone sodium phosphate – DEX-P). Data are expressed as the mean ± standard deviation and were analysed by two-way ANOVA followed by post hoc Bonferroni test. ** significant at p < 0.01 for the same DEX form and time.

Article Snippet: All printed solid forms and the PCL, DEX, DEX-A and DEX-P raw materials had their X-ray powder diffraction (XRPD) behaviour analysed by a Rigaku diffractometer (Tokyo Japan), using Cu Kα (λ = 0.154056 nm) as the radiation source, 40 kV voltage, 17 mA current, and a step of 0.05 in the range of 3–60 (2θ).

Techniques: In Vitro, Standard Deviation

Journal: International Journal of Pharmaceutics: X

Article Title: 3D printed matrix solid forms: Can the drug solubility and dose customisation affect their controlled release behaviour?

doi: 10.1016/j.ijpx.2022.100153

Figure Lengend Snippet: Porosity of the printlets (PRT) prepared with different DEX forms. Porosity was calculated from the XμCT images before and after the drug release studies.

Article Snippet: All printed solid forms and the PCL, DEX, DEX-A and DEX-P raw materials had their X-ray powder diffraction (XRPD) behaviour analysed by a Rigaku diffractometer (Tokyo Japan), using Cu Kα (λ = 0.154056 nm) as the radiation source, 40 kV voltage, 17 mA current, and a step of 0.05 in the range of 3–60 (2θ).

Techniques:

Journal: Iranian Journal of Pharmaceutical Research : IJPR

Article Title: Dextran-based Nanomicelle System with Directly Ester-bound Gadolinium Chelates as a Magnetic Resonance Imaging Contrast Agent for Tumor Detection

doi:

Figure Lengend Snippet: Schematic of MRI contrast agent synthesis. (a) Synthesis of DEX-DTPA. (b) Synthesis of DSA-DEX-DTPA. (c) Synthesis of DSA-DEX-DTPA-Gd

Article Snippet: Materials DEX (average MW 20 kDa), diethylenetriaminepentaacetic acid dianhydride (DTPA-dianhydride), 4-dimethylaminopyridine (DMAP), anhydrous DMSO, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were purchased from Shanghai Aladdin Bio-chem Technology Co., Ltd. (Shanghai, China).

Techniques:

Journal: Iranian Journal of Pharmaceutical Research : IJPR

Article Title: Dextran-based Nanomicelle System with Directly Ester-bound Gadolinium Chelates as a Magnetic Resonance Imaging Contrast Agent for Tumor Detection

doi:

Figure Lengend Snippet: 1 H NMR spectra of A) DEX, B) DTPA, and C) DSA-DEX-DTPA in D 2 O

Article Snippet: Materials DEX (average MW 20 kDa), diethylenetriaminepentaacetic acid dianhydride (DTPA-dianhydride), 4-dimethylaminopyridine (DMAP), anhydrous DMSO, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were purchased from Shanghai Aladdin Bio-chem Technology Co., Ltd. (Shanghai, China).

Techniques:

Journal: Iranian Journal of Pharmaceutical Research : IJPR

Article Title: Dextran-based Nanomicelle System with Directly Ester-bound Gadolinium Chelates as a Magnetic Resonance Imaging Contrast Agent for Tumor Detection

doi:

Figure Lengend Snippet: Physicochemical properties of DEX-based contrast agents

Article Snippet: Materials DEX (average MW 20 kDa), diethylenetriaminepentaacetic acid dianhydride (DTPA-dianhydride), 4-dimethylaminopyridine (DMAP), anhydrous DMSO, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were purchased from Shanghai Aladdin Bio-chem Technology Co., Ltd. (Shanghai, China).

Techniques:

Journal: Iranian Journal of Pharmaceutical Research : IJPR

Article Title: Dextran-based Nanomicelle System with Directly Ester-bound Gadolinium Chelates as a Magnetic Resonance Imaging Contrast Agent for Tumor Detection

doi:

Figure Lengend Snippet: In-vitro cytotoxicity of DSA-DEX-DTPA-Gd and Magnevist® to SW 1990 cells in culture exposed for 48 h (n = 5).

Article Snippet: Materials DEX (average MW 20 kDa), diethylenetriaminepentaacetic acid dianhydride (DTPA-dianhydride), 4-dimethylaminopyridine (DMAP), anhydrous DMSO, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were purchased from Shanghai Aladdin Bio-chem Technology Co., Ltd. (Shanghai, China).

Techniques: In Vitro

Journal: Iranian Journal of Pharmaceutical Research : IJPR

Article Title: Dextran-based Nanomicelle System with Directly Ester-bound Gadolinium Chelates as a Magnetic Resonance Imaging Contrast Agent for Tumor Detection

doi:

Figure Lengend Snippet: T 1 -weighted images of pancreatic tumors generated by using Magnevist®, DSA-DEX-DTPA-Gd, and DSA-DEX- NH -DTPA-Gd (arrows indicate in-situ pancreatic tumors).

Article Snippet: Materials DEX (average MW 20 kDa), diethylenetriaminepentaacetic acid dianhydride (DTPA-dianhydride), 4-dimethylaminopyridine (DMAP), anhydrous DMSO, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were purchased from Shanghai Aladdin Bio-chem Technology Co., Ltd. (Shanghai, China).

Techniques: Generated, In Situ

Journal: Iranian Journal of Pharmaceutical Research : IJPR

Article Title: Dextran-based Nanomicelle System with Directly Ester-bound Gadolinium Chelates as a Magnetic Resonance Imaging Contrast Agent for Tumor Detection

doi:

Figure Lengend Snippet: Change in relaxation rates, ΔR 1 following intravenous injection of Magnevist®, DSA-DEX-DTPA-Gd, and DSA-DEX- NH -DTPA-Gd

Article Snippet: Materials DEX (average MW 20 kDa), diethylenetriaminepentaacetic acid dianhydride (DTPA-dianhydride), 4-dimethylaminopyridine (DMAP), anhydrous DMSO, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were purchased from Shanghai Aladdin Bio-chem Technology Co., Ltd. (Shanghai, China).

Techniques: Injection